Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Blend · Tortoise

Patient Opportunity Trust Class A (LGOAX)

Ticker LGOAX · Since 2009-02-03 · · Holdings as of Jun 30, 2026

Expense ratio
1.69%$169/yr per $10k
5-yr return
+5.5%annualized
1-yr return
+20.0%as of Dec 2025
Net assets
$2.0Ball share classes
Holdings
38

Bottom line

Is LGOAX a good fund? The bottom line

LGOAX is the Class A share class of Patient Opportunity Trust, a managed large blend mutual fund from Tortoise.

It charges 1.69% — about $169 a year on every $10,000 invested, more expensive than 87% of large blend funds we track.

It returned +20.0% over one year, +5.5% a year over five years, +10.6% a year over ten (as of Dec 31, 2025, per its prospectus).

With $2.0 billion in net assets and 38 holdings, its largest position is Royalty Pharma PLC (7.0%) and the top 10 make up 54.8% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.69%)
  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 54.8% of assets
  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What LGOAX invests in

The Patient Opportunity Trust (the Fund) seeks long term growth of capital.

"The Fund normally makes investments that, in the portfolio managers opinion, offer the opportunity for long-term growth of capital. The portfolio managers exercise a flexible strategy in the selection of investments, not limited by investment style or asset class. The investment strategy typically involves identifying instances where the Advisor believes the capital markets have mispriced investment opportunities and exploiting price discrepancies and inefficiencies in the market. The Fund may invest without limit in the common stock of U.S. and foreign issuers (including securities denominated in foreign currencies) of all sizes and in other U.S. and foreign securities, including emerging markets, and including: securities convertible into common stock; securities issued through private placements; preferred securities; warrants and rights; securities issued by investment companies…

From the fund's prospectus (filed Apr 30, 2026).

LGOAX performance

Fund calendar-year total returns, 2016–2025 2016: −0.3%; 2017: +26.0%; 2018: −9.8%; 2019: +33.9%; 2020: +38.6%; 2021: −3.2%; 2022: −36.1%; 2023: +39.3%; 2024: +26.3%; 2025: +27.4% −0% 2016 +26% 2017 −10% 2018 +34% 2019 +39% 2020 −3% 2021 −36% 2022 +39% 2023 +26% 2024 +27% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
LGOAX+20.0%+5.5%+10.6%
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full LGOAX performance history →

What LGOAX costs

On a $10,000 investment, LGOAX's 1.69% expense ratio costs about $169 a year. The prospectus estimates $2,458 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full LGOAX fee table →

LGOAX top 10 holdings

#Holding% of fund
1Royalty Pharma PLC RPRX6.98%
2Citigroup Inc C6.97%
3Alphabet Inc GOOGL6.67%
4UnitedHealth Group Inc UNH6.21%
5Amazon.com Inc AMZN5.64%
6NVIDIA Corp NVDA4.98%
7CVS Health Corp CVS4.51%
8QXO Inc QXO4.48%
9Norwegian Cruise Line Holdings NCLH4.21%
10Precigen Warrant Restricted4.19%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 54.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to LGOAX

More funds like LGOAX →

LGOAX FAQ

What is the expense ratio of LGOAX?
LGOAX's expense ratio is 1.69%, which works out to about $169 a year for every $10,000 invested. The prospectus estimates total costs of $2,458 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is LGOAX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.69%); 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 54.8% of assets; front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does LGOAX hold?
LGOAX's largest holdings are Royalty Pharma PLC (7.0%), Citigroup Inc (7.0%), Alphabet Inc (6.7%), UnitedHealth Group Inc (6.2%), Amazon.com Inc (5.6%). It holds 38 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is LGOAX's 5-year return?
LGOAX returned +5.5% a year over the five years ending Dec 31, 2025, and +10.6% a year over ten years. Past performance does not guarantee future results.
Does LGOAX have a sales load?
Yes. LGOAX has a maximum front-end sales charge of 5.75%. It may charge a deferred sales charge of up to 1% if sold early.
Who manages LGOAX?
LGOAX is offered by Tortoise through Advisor Managed Portfolios.